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Abstract
Epoxyeicosatrienoic acids (EETs) are cardioprotective mediators metabolized
by soluble epoxide hydrolase (sEH) to form corresponding diols (DHETs). As
a sex-susceptible target, sEH is involved in the sexually dimorphic regulation
of cardiovascular function. Thus, we hypothesized that the female sex favors
EET-mediated potentiation of cardiac function via downregulation of sEH
expression, followed by upregulation of peroxisome proliferator-activated
receptors (PPARs). Hearts were isolated from male (M) and female (F) wild-
type (WT) and sEH-KO mice, and perfused with constant flow at different pre-
loads. Basal coronary flow required to maintain the perfusion pressure at
100 mmHg was significantly greater in females than males, and sEH-KO than
WT mice. All hearts displayed a dose-dependent decrease in coronary resis-
tance and increase in cardiac contractility, represented as developed tension in
response to increases in preload. These responses were also significantly greater
in females than males, and sEH-KO than WT. 14,15-EEZE abolished the sex-
induced (F vs. M) and transgenic model-dependent (KO vs. WT) differences in
the cardiac contractility, confirming an EET-driven response. Compared with
M-WT controls, F-WT hearts expressed downregulation of sEH, associated
with increased EETs and reduced DHETs, a pattern comparable to that
observed in sEH-KO hearts. Coincidentally, F-WT and sEH-KO hearts exhib-
ited increased PPARa expression, but comparable expression of eNOS, PPARb,
and EET synthases. In conclusion, female-specific downregulation of sEH initi-
ates an EET-dependent adaptation of cardiac function, characterized by
increased coronary flow via reduction in vascular resistance, and promotion of
cardiac contractility, a response that could be further intensified by PPARa.
Introduction
The incidence of ischemic heart diseases distributes in a
sexually dimorphic manner, as evidenced by the signifi-
cantly lower incidence in females than age-matched males,
which is due at least in part, to the better cardiac perfusion
in women (Gura 1995; Huang and Kaley 2004). A potential
gene involved in the sexual dimorphism of cardiovascular
diseases is the Ephx2 that encodes for the protein of soluble
epoxide hydrolase (sEH) and is responsible for converting
cardioprotective mediators, namely epoxyeicosatrienoic
acids (EETs; members of epoxy fatty acid family), to
their corresponding non- or less bioactive diols (dihydrox-
yeicosatrienoic acids, DHETs) (Kersten et al. 2000;
Mark-Kappeler et al. 2011; Harris and Hammock 2013).
Therefore, sEH is a susceptible gene for hypertension-
associated cardiovascular diseases (Kersten et al. 2000; Ai
et al. 2007). A review of the literature shows that potentia-
tion of EET bioavailability through compromising EET
degradation, via either knockout of the Ephx2 gene or by
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pharmacological inhibition of the enzyme, evokes cardio-
vascular protective actions (Qin et al. 2015a,b). However,
the nature of disruption of the Ephx2 gene affecting blood
pressure (Luria et al. 2007) and vascular responsiveness
(Kandhi et al. 2015b; Qin et al. 2015a) in a sex-different
manner remains to be clarified. Findings of sexual dimor-
phism in the regulation of sEH expression/or activity were
originally reported in the 1980s, when the results were
exclusively obtained from the liver and kidney of rodents,
but reported without functional relevance (Gill and Ham-
mock 1980; Meijer et al. 1987; Denlinger and Vesell 1989;
Pinot et al. 1995). Only currently has the sexually dimor-
phic regulation of sEH come to the forefront of research to
specifically address sEH-dependent detrimental actions in
the pathogenesis of cardiovascular diseases. Later studies
by Alkayed’s group revealed a sex-specific phenotype, char-
acterized as a female/estrogen-dependent suppression of
sEH in the cerebral circulation, a mechanism that is
believed to be responsible for the female-favorable protec-
tion from cerebral ischemic damages such as stroke (Koer-
ner et al. 2008; Fairbanks et al. 2012; Davis et al. 2013;
Zuloaga et al. 2014). It is worth noting that the aforemen-
tioned studies regarding the sexually dimorphic regulation
of sEH in the cerebral circulation were conducted exclu-
sively on pathological models, such as cerebral artery occlu-
sion, or exposure of cultured neuronal and cerebral artery
endothelial cells to oxygen–glucose deprivation. Therefore,
research aiming to determine the physiological significance
of sex-differential regulation of sEH has been left unad-
dressed. To date, we have provided evidence indicating that
female-specific downregulation of sEH expression in coro-
nary, mesenteric, and skeletal muscle arterioles contributes
significantly to the attenuation of pressure-induced coro-
nary vasoconstriction (Froogh et al. 2016) and potentiation
of shear stress-induced vasodilation (Qin et al. 2015a).
While we have also demonstrated that genetic deletion or
pharmacological inhibition of sEH enhances coronary per-
fusion to improve cardiac function (Qin et al. 2015b), the
specific role of sex in the physiologically control of cardiac
function via EET/sEH signaling remains unknown.
On the other hand, highly expressed peroxisome prolif-
erator-activated receptor-a (PPARa) in the myocardium
has been demonstrated to serve as an essential player in
the regulation of cardiac oxidation of fatty acids (Des-
vergne et al. 2006), which are a major energy source neces-
sary for heart contractility (Lopaschuk et al. 1994). PPARs
are transcription factors that regulate and target gene tran-
scription via a ligand-dependent reporter binding, which
provides the molecular basis for an EET-attributable acti-
vation of PPARs through their actions as PPAR ligands
(Kersten et al. 2000). Within the signaling networks of
fatty acid metabolism via estrogen/CYP/EETs/sEH, PPARs
serve as the central mediator either as a downstream target
of EETs or an upstream initiator of estrogen/CYP (Imig
et al. 2005) actions. Indeed, the crucial role of PPARa in
the conduction of cardiac metabolic regulatory programs
has been well documented (Burkart et al. 2007). Based on
evidence that sEH can be targeted in a sexually dimorphic
manner and activation of PPAR signaling is linked to EET
bioactivity (Kersten et al. 2000; Harris and Hammock
2013), we hypothesized that the female sex favors the EET-
dependent adaptation of cardiac function via downregula-
tion of sEH expression to increase cardiac EET bioavail-
ability, the response that might be in turn enhanced by
reciprocal activation of PPAR signaling.
Materials and Methods
Animals
Twelve- to fifteen-week-old male (M) and female (F)
Ephx2/ (sEH-KO) and wild-type (WT) mice, abbrevi-
ated as M-KO, F-KO, M-WT, and F-WT, respectively,
were used. As described previously (Sun et al. 2014; Qin
et al. 2015b), cryorecovered heterozygous (Ephx2+/,
B6.129X-Ephx2tm1Gonz/J) and WT (Ephx2+/+, C57BL/
6J) mice were received from Jackson laboratory (Bar Har-
bor, ME) and the homozygous (Ephx2/) sEH-KO mice
were developed in the Department of Comparative Medi-
cine, New York Medical College.
All protocols were approved by the Institutional Ani-
mal Care and Use Committee of New York Medical Col-
lege and conform to the guidelines of the National
Institutes of Health and the American Physiological Soci-
ety for the use and care of laboratory animals.
Measurement of blood pressure
Mice were anesthetized by inhalation of Isothesia (isoflurane).
Blood pressure was recorded using carotid artery catheteriza-
tion and a flow-through pressure transducer (TRN050; Kent
Scientific, Torrington, CT). The heart rate of anesthetized
mice was controlled at approximately 480 beats per minute
by adjusting the depth of anesthesia when the blood pressure
was measured (Kandhi et al. 2015b; Qin et al. 2015a,b).
Isolated perfused hearts
As described previously (Qin et al. 2015b), mice were
anesthetized with isoflurane, and heparin (100U) was
injected intraperitoneally. The thorax was then opened.
The heart was excised and immediately mounted via the
ascending aorta onto a perfusion apparatus. The heart
was perfused with a nonrecirculating physiological salt
solution (PSS) containing (in mmol/L) NaCl 117, KCl
4.7, MgSO4 1.1, KH2PO4 1.2, glucose 5.5, CaCl2 2.5,
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pyruvate 2.0, ascorbate 0.1, L-arginine 0.1, and NaHCO3
24. The PSS was gassed in a water-jacketed (37°C) reser-
voir with 95% O2 to 5% CO2 to a pH value of 7.4. The
perfusate was pumped through an in-line 1-lm filter
using a Rainin peristaltic pump. A 2-mL bubble trap, a
water-jacketed (37°C) heating coil, and a T-adaptor con-
necting a pressure transducer (P23XL, Grass) were
sequentially connected to the heart. A metal hook made
from a 31-gauge needle was penetrated through the left
ventricle at the apex of the heart to drain the Thebesian
fluid accumulated in the ventricle. The other end of the
hook was attached to a force transducer (FTO3C, Grass)
to control and record tension and heart rate. The heart
was immersed in the coronary effluent solution in a
water-jacketed (37°C) tissue bath (10 mL, Radnoti) and
perfused with a constant flow. Changes in perfusion pres-
sure and end-diastolic and peak systolic tensions were
continuously recorded. At the beginning of experiments,
the flow rate was rapidly increased to reach a perfusion
pressure of 100 mmHg. During the equilibration, changes
(increases) in perfusion pressure as a consequence of
development of myogenic constriction in coronary arter-
ies were continuously adjusted by reducing flow rate to
maintain a perfusate pressure at 100 mmHg. The heart
reached an equilibrated status (a constant perfusion pres-
sure of 100 mmHg and a constant heart rate of above
320 beats per min) within 15 min. The flow rate provided
to obtain a constant perfusion pressure of 100 mmHg
was considered as basal coronary flow and was kept con-
stant throughout experiments. After basal flow was
obtained, tension was increased from 0 to 4 g in 0.5 g
increments to initiate a stepwise increase in end-diastolic
tension of the heart. At each tension step, changes in per-
fusion pressure were continuously recorded for 5 min on
a DI-700 data acquisition system (DATAQ).
In separate groups of mice, 14,15-epoxyeicosa-5(Z)-
enoic acid (14,15-EEZE, 105mol/L; a putative pan-EET
receptor antagonist) was added into the PSS. Hearts were
perfused with inhibitor-containing PSS for 45 min and
then changes in perfusion pressure/developed tension in
responses to stepwise increases in diastolic tension were
recorded.
LC/MS/MS-based measurements for cardiac
EETs and DHETs
Isolated hearts were pulverized in liquid nitrogen. Phos-
pholipids were extracted with the Bligh–Dyer method
from 30 to 50 mg of heart tissue. EETs and DHETs were
extracted with ethyl acetate following alkali hydrolysis of
the phospholipids to release esterified EETs or DHETs
and quantified with a Q-trap 3200 linear ion trap quadru-
ple LC/MS/MS (AB ScieX; Qtrap 3200) equipped with a
Turbo V ion source operated in negative electrospray
mode (Applied Biosystems, Foster City, CA), as described
previously (Sun et al. 2014; Kandhi et al. 2015b; Qin
et al. 2015a,b). Protein concentration of samples was
determined by the Bradford method (Bio-Rad, Hercules,
CA) and was used to normalize the detected lipids. Data
for total EET and DHET levels, as well as for each of the
four regioisomeric EETs and DHETs are presented and
expressed as pg/mg protein.
Western blot analysis
Isolated hearts were pulverized in liquid N2. Equal amounts
of total protein (25 lg) extracted from hearts were loaded
onto and separated by a 10% SDS-PAGE gel and trans-
ferred to a PVDF membrane. The membrane was probed
with specific primary antibodies for sEH (1:800 dilution),
PPARa and PPARb (1:500), eNOS (1:200), CYP2J2 (1:800)
(Santa Cruz Biotechnology, Inc., Paso Robles, CA) and
CYP2C9 (1:1000; Biodesign Inc. Maco, ME), and appropri-
ate secondary antibodies conjugated with horseradish per-
oxidase (1:5000). Specific bands were visualized with a
chemiluminescence kit (Thermo Scientific, Rockford, IL)
and normalized to GAPDH. The X-ray film was scanned
into a computer and band densitometry was digitalized
with UN-SCAN-IT software (Silk Scientific, Orem, UT).
Calculation and statistical analysis
Data are expressed as mean  SE, and n refers to the
number of mice. Basal coronary flow was recorded at a
constant pressure of 100 mmHg and normalized to the
heart weight, and expressed as mL/min/g. Coronary vas-
cular resistance was calculated by the formula of R = P/F,
where P and F are indicative of perfusion pressure and
flow, respectively, and expressed as mmHg/min per mL.
Analyses of linear regression and the comparison of the
slope of regression lines between multiple groups were
performed using GraphPad Prism software (GraphPad
Software, Inc., La Jolia, CA). Analyses of blood pressure,
cardiac EET and DHET levels, and coronary basal flow
were performed using one-way ANOVA followed by the
Tukey–Kramer post hoc test. Student’s t-test or paired
t-test was used where appropriate. Statistical significance
was accepted at a level of P < 0.05.
Results
Reduced blood pressure in female WT and
sEH-deficient mice
Mouse mean arterial blood pressure (MAP) was recorded:
M-WT (n = 6): 93.5  0.4 mmHg; F-WT (n = 8):
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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84.5  0.5 mmHg; M-KO (n = 6): 83.2  0.5 mmHg;
and F-KO (n = 6): 78.5  1.0 mmHg. Female mice
(F-WT and F-KO) had significantly lower MAP than their
male (M-WT and M-KO) counterparts (P < 0.05). Com-
pared to M-WT mice, deletion of the sEH gene (M-KO)
significantly reduced blood pressure (P < 0.05) to a level
comparable to that of F-WT mice. F-KO mice had the
lowest MAP among the four groups of mice. The results
revealed that the female sex potentiated sEH deficiency-
induced reductions in blood pressure.
Sex-different regulation of cardiac EET
metabolism
Table 1 summarizes each individual EET and DHET
regioisomer in the myocardium of the four groups of
mice. The total levels of EETs and DHETs, as well as the
ratio of EETs/DHETs are depicted in Figure 1. Figure 1
indicates several points: (1) M-KO mice exhibited a sig-
nificant increase in total EETs (A) as a consequence of
decreased conversion of EETs into DHETs (B), leading to
a greater ratio of EETs/DHETs compared to M-WT con-
trols (C), thereby confirming the disruption of the Ephx2
gene. (2) Compared to M-WT, F-WT mice exhibited a
significantly greater ratio of EETs/DHETs as a result of
increased EETs and decreased DHETs, suggesting a sex-
different regulation of EET metabolism in normal hearts.
(3) A sex-different response to sEH deficiency was specifi-
cally indicated by the fact that F-KO mice did not initiate
statistically significant changes in cardiac EET/DHET pro-
file in comparison with F-WT controls, while significance
was observed in the cardiac EET/DHET ratio of M-KO
mice compared to their M-WT mice. (4) The identical
pattern of cardiac EET metabolism in F-WT, F-KO, and
M-KO mice implies the presence of redundant/or over-
lapping regulatory mechanism(s) between female sex and
sEH deficiency.
Female sex and sEH deficiency increase
basal coronary flow
Figure 2 summarizes data of basal coronary flow normal-
ized to heart weight, revealing that in order to maintain a
constant perfusion pressure of 100 mmHg, a significantly
greater basal coronary flow was required in F-WT than
M-WT mice, indicating a sex difference in the physiologi-
cal control of coronary circulation. Compared to WT con-
trols, sEH-KO hearts required further increases in basal
flow to maintain the perfusion pressure at 100 mmHg,
and this increment exhibited a greater predominance in F-
KO than M-KO mice. These results indicate that sEH-defi-
ciency initiates an increase in basal coronary flow, a
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Female sex favors sEH deficiency-induced
potentiation of cardiac work
Changes in perfusion pressure, expressed as changes in
vascular resistance (y-axis), were recorded in response to
stepwise increases in end-diastolic tension (x-axis) in
hearts. As depicted in Figure 3, coronary resistance at
zero tension was inversely proportional to the level of
basal perfusion flow shown in Figure 2. Increases in end-
diastolic tension dose dependently reduced vascular resis-
tance in all groups of hearts. F-WT hearts displayed a sig-
nificantly greater magnitude of reduction at each preload,
as well as at the rate of reduction, which was manifested
by a deeper slope of the regression line compared to M-
WT hearts (P = 0.0123). This suggests a female-favorable
modulation of coronary resistance during cardiac work.
Moreover, deletion of the sEH gene initiated a signifi-
cantly drastic reduction in coronary resistance in both
male and female (M-KO and F-KO) hearts compared to
their corresponding WT hearts. These results imply that
sEH deficiency potentiates coronary vasodilatation, via
perhaps, an EET-mediated mechanism. It is important to
note that the sex-difference in the reduction of coronary
resistance was not statistically significant between M-KO
and F-KO mice, nor was the slope of their regression
lines (P = 0.1046). In this context, the lack of significant
changes between male and female sEH-KO mice suggests
that the contribution of EETs to the response is essential,
which was further supported by an identical cardiac EET
A B C
Figure 1. Increased EETs and reduced DHETs in myocardium of sEH-KO and female WT mice. Normalized data for total levels of (A) EETs, (B)
DHETs, and (C) the ratio of EETs/DHETs in myocardium of male (M) and female (F) WT and sEH-KO mice. * indicates significant difference from
M-WT (n = 5–9). sEH, soluble epoxide hydrolase; EETs, epoxyeicosatrienoic acids; DHETs, dihydroxyeicosatrienoic acids; WT, wild type; KO,
knockout.
Figure 2. Increased basal coronary blood flow in sEH-KO and
female WT mice. Normalized data for basal coronary flow obtained
at zero preload, from M-WT (n = 8), F-WT (n = 7), M-KO (n = 7),
and F-KO (n = 6) mice, respectively. * indicates a significant
difference from M-WT. # indicates a significant difference from
F-WT and M-KO, respectively.
Figure 3. Attenuation of coronary resistance in sEH-KO and female
WT mice. The correlation between coronary vascular resistance and
end-diastolic tension in isolated hearts of M-WT, F-WT, M-KO, and
F-KO mice. Correlation coefficients in the four groups of mice are
0.9748 (P < 0.05; M-WT), 0.9999 (P < 0.01; F-WT), 0.9965
(P < 0.01; M-KO), and 0.9965 (P < 0.01; F-KO), associated with
the slope of their regression lines of 3.108  0.5026,
5.374  0.1669, 4.715  0.2795, and 3.951  0.2334,
respectively. The difference in the slope between M-WT and F-WT,
as well as M-WT versus M-KO, is statistically significant (P = 0.0123
and P = 0.04842, respectively) (n = 6–8 for each group).
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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metabolic profile between M-KO and F-KO mice
(Fig. 1).
Developed tension (y-axis of Fig. 4B and C), repre-
sented as a difference between peak systolic and end-dia-
stolic tension (Fig. 4A) in response to increases in end-
diastolic tension (x-axis) was used as an index of cardiac
contractility (Qin et al. 2015b). As summarized in Fig-
ure 4B, all groups of hearts displayed dose-dependent
increases in developed tension. Generally, the increment
in cardiac contractility was greater in F-KO >
M-KO = F-WT > M-WT mice, respectively, associated
with a deeper slope of the regression line in F-KO than
M-KO mice (P = 0.026), as well as a tendency toward a
deeper slope in F-WT than M-WT mice (P = 0.063).
Although there was a parallel upward shift in the devel-
oped tension curve in M-KO compared to that of F-WT
mice, their increment at each preload level appeared iden-
tical (Fig. 4B), resulting in a comparable slope of the two
regression lines (P = 0.478). These results coincided with
those shown in Figure 1, indicating two issues: (1) dis-
ruption of the sEH gene in males (M-KO) evokes the
same cardiac behaviors as those in F-WT mice, alluding
to the presence of female-specific properties that imitates
actions of sEH deficiency in males; and (2) an additional
knockout of the sEH gene in females (F-KO) further pro-
motes cardiac contractility in a “dose-like”-dependent
manner in comparison with F-WT and M-KO mice,
revealing an additive/or synergistic effect between the
female sex and sEH deficiency.
Potentiation of cardiac contraction via an
EET-dependent mechanism
Specific contribution of EETs to the enhanced cardiac
contractility in F-WT, F-KO, and M-KO mice (Fig. 4B)
was evaluated using an EET inhibitor. Since our prelimi-
nary study confirmed that there were no effects of 14,15-
EEZE on normal male hearts, we therefore used M-WT
hearts as controls to compare the EEZE-induced changes
in the other three groups of mice. Figure 4C shows that
14,15-EEZE caused a downward shift in the developed
tension curves of F-WT, F-KO, and M-KO mice, return-
ing the originally enhanced cardiac contractility in the
three groups of mice back to the comparable levels seen
in M-WT hearts. Consequently, neither the increment in




Figure 4. EET-dependent promotion of cardiac contractility in sEH-KO and female WT mice. (A) Tracings of heart contraction (peak systolic
tension) in response to 0.5 g end-diastolic tension in M-WT, F-WT, M-KO, and F-KO mice. (B) Linear relationships between the developed
tension (y-axis: difference of peak systolic tension and end-diastolic tension) and end-diastolic tension (x-axis) in the four groups of mice.
Correlation coefficient equals 0.9702 (P = 0.0298; M-WT), 0.9910 (P = 0.009; F-WT), 0.9950 (P = 0.005; M-KO), and 0.9960 (P = 0.0038;
F-KO), associated with corresponding slopes of regression lines of 0.09834  0.01737, 0.1570  0.01498, 0.1721  0.01217, and
0.3299  0.02044, respectively. The statistically significant difference in the slope of regression line was presented between M-KO and F-KO
(P = 0.0261), M-WT versus M-KO (P = 0.02616), F-WT versus F-KO (P = 0.002358), and M-WT versus F-KO (P = 0.000978), whereas
statistically insignificant between M-WT and F-WT mice (P = 0.06344). (C) The developed tension curves of the four groups of hearts that were
subjected to 14,15-EEZE for 45 min. Correlation coefficient equals 0.9702 (P = 0.0298, M-WT), 0.9983 (P = 0.0017; F-WT), 0.9571
(P = 0.0429; M-KO), and 0.9939 (P = 0.0061; F-KO), associated with their corresponding slopes of regression lines of 0.09834  0.01737,
0.1065  0.004419, 0.1835  0.0393, and 0.1332  0.01049, respectively. There was no significant difference among all groups (n = 5–8
for each group).
2016 | Vol. 4 | Iss. 12 | e12838
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significantly different among the groups, as illustrated by
four statistically comparable curves. These data indicate
that the difference in cardiac contractility between the
sexes (male vs. female) and between different transgenic
models (WT vs. KO) was essentially mediated by EETs.
Notably, 14,15-EEZE abolished the significant differences,
but failed to completely reverse the developed tension
curve in F-WT and sEH-KO hearts to the same level as
that in M-WT hearts, due perhaps, to its lower efficiency
in inhibiting other isoforms of EETs, including 5,6-; 8,9-;
or 11,12-EET, respectively.
Figure 5 provides molecular evidence from western
blot analysis. The original and summarized data indicate
that protein expression of sEH in myocardial tissue was
significantly suppressed in F-WT compared to M-WT
mice (Fig. 5A) and was undetectable in sEH-KO mice
(Fig. 5B). Protein expression of PPARa (a major subunit
of PPAR families expressed in the heart) was significantly
increased in myocardium of F-WT, M-KO, and F-KO
compared to M-WT mice; and was significantly greater
in F-KO than F-WT and M-KO hearts (Fig. 5C), thus
suggesting synergetic effects between female sex and EETs
in the promotion of PPARa expression. By contrast,
expression of PPARb remained comparable in the four
groups of mice (Fig. 5D), further confirming the speci-
ficity for PPARa involvement in the pathway. Protein
expression of eNOS, CYP2J2 (a major cardiac EET syn-
thase), and CYP2C9 (a major EET synthase of vascular
endothelium) was comparable among the four groups of
mice (Fig. 5E).
Discussion
This study demonstrates the following four major find-
ings. First, sEH deficiency increases coronary blood flow
that was attributed to the reduced vascular resistance in
both basal condition (Fig. 2) and during cardiac work
(Figs. 3, 4). Second, cardiac contractility in males and
females exhibited different responses when the hearts were
challenged with the same increase in preload, character-
ized as significantly greater responses in F-WT than M-
WT, and in F-KO than M-KO mice, respectively (Fig. 4A
and B). Third, blockade of EET bioavailability essentially
abolished the differences in cardiac contractility (Fig. 4C),
clarifying the nature of EET-driven responses. Finally, the
genetic deletion and downregulation of sEH (Fig. 5A)
increased cardiac EETs (Fig. 1), and was accompanied by
a secondary upregulation of PPARa expression (Fig. 5C),
suggesting PPARa is a downstream mediator of EET-
dependent signaling. As a result, the activation of EETs
and subsequent activation of PPARa reciprocally con-
tribute to the adaptation of cardiac performance. Given
that the disruption of the sEH gene in males (M-KO)
evokes the same action as downregulation of sEH in F-
WT mice, an additional sEH knockout in the latter
(F-KO) further promotes the response, and that both
sexually dimorphic (male vs. female) and transgenic-
dependent (WT vs. KO) differences are prevented by the
inhibition of EETs, we therefore draw the conclusion that
the reciprocal actions of female sex-specific and sEH/
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Figure 5. Female-specific downregulation of sEH and EET-
dependent upregulation of PPARa. Western blot analysis for protein
expression of sEH (A and B), PPARs (C and D), and eNOS, CYP2J2,
and CYP2C9 (E) in hearts of the four groups of mice. * indicates
significant difference from M-WT. # indicates significant difference
from F-WT and M-KO (n = 3 blots for each summarized data).
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promotion of cardiac performance, a process that could
be amplified by the activation of PPAR signaling.
sEH deficiency benefits coronary perfusion,
as a function of reduced vascular resistance
Under physiological conditions, increases in EETs (Fig. 1)
were capable of eliciting a significant decline in vascular
resistance (Fig. 3), attributing to the EET-dependent
coronary vasodilator properties and subsequently increas-
ing coronary blood flow (Fig. 2). Particularly, the cardiac
EET metabolic pattern (Fig. 1) matched up with the phe-
notypes of basal coronary flow (Fig. 2) and cardiac per-
formance in working hearts challenged with increases in
preload (Figs. 3, 4). Because of the comparable expression
of EET synthases (CYP2J2 and CYP2C9; Fig. 5E), the
increased cardiac EETs resulted mainly from compro-
mised EET hydrolysis/degradation (Table 1 and Fig. 1).
To this end, a physiologically based EET-dependent adap-
tation of coronary circulation in normal hearts was clari-
fied, and provides a mechanistic rationale for the clinical
development of sEH inhibitors as a therapeutic strategy
in the treatment of ischemic heart diseases (Imig 2006;
Imig and Hammock 2009). It is worth noting that in the
pulmonary circulation, a female-driven increase in pul-
monary EETs did not significantly affect basal right ven-
tricular systolic pressure (RVSP), but did elicit great
alterations in RVSP when animals were challenged with
thromboxane analog (Kandhi et al. 2015b) or exposed to
hypoxia (Kandhi et al. 2015a), insinuating a conditional-
based characteristic of EETs in the pulmonary circulation.
In the heart, however, the functional value of EETs is pre-
dominantly discernible in both basal and stimulated con-
ditions, suggesting that EETs are vital players in the
regulation of coronary circulation.
Female sex favors sEH deficiency-dependent
adaptation of cardiac function
We found that the reduction in coronary resistance
(Fig. 3), increases in coronary flow (Fig. 2), and cardiac
contractility (Fig. 4) were inversely correlated with the
cardiac sEH expression (Fig. 5A), but were proportional
to the expression of PPARa (Fig. 5C). Moreover, during
the process of tension development in response to heart
stretch, high cardiac EETs in F-WT and sEH-KO mice
(Fig. 1) served as major players in dilating coronary arter-
ies, which was followed by improved cardiac perfusion.
Thus, an optimal utilization of oxygen as a consequence
of better tissue perfusion could be responsible for the
promotion of cardiac work. Figure 4 clarifies two impor-
tant issues by showing that (1) during cardiac perfor-
mance, normal female hearts exhibited a greater potential
for tension development than males and (2) the sexual
dimorphism in cardiac contractility also exists in sEH null
hearts with even greater vigor. This reveals reciprocal
interaction between the female-specific and EET-depen-
dent potentiation of cardiac function, during which the
involvement of PPARs was noticed in the cross talk
between the pathways. This conclusion was drawn based
on the positive correlations among cardiac work (Fig. 4),
EET levels (Fig. 1), and PPARa expression (Fig. 5C), as
well as on evidence of the critical roles of PPARs as either
downstream targets of EETs or upstream initiators of
estrogen/CYP (Imig et al. 2005).
Mechanisms responsible for the female-
favorable actions of EETs and PPARs
The nature of EET-dependent contribution to the poten-
tiation of cardiac contractility is indicated in Figure 4C,
which shows that the inhibition of EET bioactivity elimi-
nated the differences originally presented in Figure 4B.
Female-specific downregulation of cardiac sEH expression
(Fig. 5A) provided explanations for the similar metabolic
pattern of EETs and DHETs in F-WT and sEH-KO hearts
(Fig. 1), bringing to light a functional significance for
female-facilitated actions of EETs (Figs. 2–4). Even with
an ~30% reduction in sEH expression, F-WT hearts still
maintained similar levels of EETs and DHETs to those in
sEH-KO hearts (Fig. 1). This could presumably be
explained by the simultaneous presence of reduced sEH
activity, in addition to the downregulation of its protein
expression. Indeed, previous studies reported that in
mouse cerebral arteries, livers, and kidneys, sexually
dimorphic changes in sEH gene expression were accom-
panied by the same change in its enzymatic activity
(Pinot et al. 1995; Zhang et al. 2009).
It has been concluded that female sex and/or estrogens
favor the contribution of EETs over other vascular media-
tors including NO (Scotland et al. 2005; Vasudevan et al.
2005). For instance, in the clinically failing human heart,
a condition associated with significantly impaired NO
synthesis and downregulated PPARa expression (Kar-
bowska et al. 2003), myocyte necrosis and apoptosis were
significantly lower in females than in males, leading to a
longer duration of the process and a later onset of cardiac
decompensation in women (Guerra et al. 1999). These
female-specific cardioprotections are dependent at least in
part, upon the EET-attributable protection against car-
diomyocyte necrosis and apoptosis (Oni-Orisan et al.
2014), as well as EET-dependent stimulation of PPAR sig-
naling via their actions as PPAR ligands (Kersten et al.
2000). On the other hand, in physiological conditions,
the heart derives most of the energy necessary for its con-
tractile function from fatty acid oxidation (Lopaschuk
2016 | Vol. 4 | Iss. 12 | e12838
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et al. 1994). SEH metabolizes epoxides of fatty acids more
rapidly than other substrates (Pinot et al. 1995). As such,
in addition to an optimal utilization of oxygen as a func-
tion of greater vasodilation-induced improved tissue per-
fusion, promoting the uptake of fatty acids such as EETs
as a cardiac substrate preserves the energy potential of
hearts (Recchia et al. 1999). Since fatty acids function as
a primary energy source for cardiac work and their
uptake is promoted by PPARs (Goto et al. 2013), and
additional increases in EET bioactivities can in turn acti-
vate PPAR signaling (Ng et al. 2007), it is plausible to
speculate that with downregulation of, or deficiency in
sEH in F-WT and sEH-KO mice, cardiomyocytes are able
to optimally utilize EETs as energy substrates, while the
subsequent EET-dependent activation of PPAR signaling
can further lead to vigorous uptake of EETs by the myo-
cardium (Ng et al. 2007; Goto et al. 2013) to form a pos-
itive feedback loop. The upregulation of PPARa occurs in
not only F-WT, but also in M-KO mice as well (Fig. 5C),
and additional knockout of the sEH gene in females
(F-KO) elicited further “dose-like”-dependent increases in
PPARa expression that is accompanied by greater cardiac
contractility (Fig. 4) compared with F-WT and M-KO
mice. These findings, therefore, strongly suggest that
PPARa can be a downstream mediator that is triggered
by EETs in female-susceptible manner. As such, a female-
driven potentiation of EETs, associated with consequential
activation of downstream located PPARa, works in con-
cert to support ATP synthesis and drive cardiac perfor-
mance into high gear. Indeed, the functional significance
of PPARa has been further highlighted by studies indicat-
ing that suppression of PPARa in the failing human heart
contributes significantly to the reduction in fatty acid uti-
lization, leading to the formation of “energy starved”
hearts (Karbowska et al. 2003), a situation that can be
reversed by PPARa agonists via recruitment of myocardial
ATP production (Sarma et al. 2012).
Taken together, the presence of interactions among the
sex/gender, sEH expression and EET metabolism, PPAR
signaling, and cardiac reactivity have brought us to make
the conclusion that there is a female-favorable adaptation
of cardiac function via an EET-dependent signaling that
is amplified by activation of PPARs (Fig. 6).
Perspectives and alternatives
This study demonstrates that innate female suppression of
sEH expression generates a duplicated/overlapping disrup-
tion of the sEH gene in the EET-initiated improvement of
cardiac function. This mechanism may explain, at least in
part, the “paradox” of the minimal hypotensive effect
exhibited in female mice in response to knockout of Ephx2
gene (Luria et al. 2007), and also further supports our
previous findings that show an identical phenotype of vas-
cular responsiveness to flow/shear stress (Qin et al. 2015a)
and to intravascular pressure (Froogh et al. 2016), as well
as the similarities in the pulmonary arterial responses to
EETs (Kandhi et al. 2015b) between F-WT and sEH-KO
mice. Sex differences in the cardiovascular systems have
been believed to be intrinsically attributed to sex chromo-
some-dependent differences in gene expression, which can
be further modified by sex hormones, leading to the sex-
specific gene expression and function (Garcia et al. 2016).
To this end, our aim for future studies is to explore molec-
ular mechanisms involving the female hormone/estrogen-
dependent epigenetic regulation of sEH via the DNA
methylation-induced silencing of sEH transcription. On
the other hand, while we have shed light on a beneficial
modification of PPARa expression as the function of
female sex and EETs, its causative role, if any, in the pro-











Figure 6. Schematic illustration of the positive feedback loop
during the process of EET-dependent potentiation of cardiac work.
Genetic disruption, or female-specific downregulation of sEH
(Fig. 5A) (Meijer et al. 1987; Pinot et al. 1995; Harris and
Hammock 2013) and female-induced upregulation of PPARa
(Fig. 5B) (Imig et al. 2005) cause increases in energy substrates of
free fatty acids (FFA and EETs, Fig. 1) (Recchia et al. 1999) and
their uptake (Lopaschuk et al. 1994). EETs per se in turn, stimulate
PPARa expression/activities (Fig. 5B) (Kersten et al. 2000; Imig et al.
2005; Ng et al. 2007) to initiate further vigorous uptake of EETs by
the heart (Karbowska et al. 2003; Sarma et al. 2012; Goto et al.
2013). On the other hand, EETs elicit greater vasodilation (Fig. 3)
and better cardiac perfusion (Fig. 2), and both synergistically
promote contractility of hearts (Fig. 4). ↓ indicates a stimulation;
┴ indicates an inhibition. EET, epoxyeicosatrienoic acid; sEH,
soluble epoxide hydrolase; DHETs, dihydroxyeicosatrienoic acids;
WT, wild type; KO, knockout; FFA, free fatty acids.
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